Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis
ConditionMultiple Sclerosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorClinique Neuro-Outaouais
About this trial
Study the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.
Eligibility criteria
Qualifiers
Signed informed consent.
Age ≥ 18 years and less than 71 years.
Diagnosis of MS according to the revised 2017 McDonald Criteria (Thompson et al. 2018).
EDSS of 3.0 to 6.5 with a pyramidal functional system score of 3.0 or more.
Disqualifiers
Know presence of other neurologic disorders, which in the opinion of the investigator could add to the patient's neurological disability within the timespan of the study.
Evidence of clinically significant cardiovascular (including arrhythmias), psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease that, in the investigator's opinion, would preclude patient participation.
Pregnant or breastfeeding or intending to become pregnant during the study.
Any previous rTMS therapy for any indication.
Trial design
Treatments tested in this trial
- Repetitive Transcranial Magnetic Stimulation
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Clinique Neuro-Outaouais
Lead sponsor
University of Ottawa
Collaborator
Source ClinicalTrials.gov